Launch of the Dynamic Clamp Unit for the Patchliner - the Dynamite(8)
MUNICH, Oct. 2, 2019 /PRNewswire/ -- Nanion is pleased to announce the launch of Dynamite8, a Dynamic Clamp unit for the multichannel automated patch clamp system, the Patchliner. The Dynamite8 is a Patchliner Add-On which simulates ion channel currents in cells in real-time during patch clamp experiments. This approach will allow higher throughput recordings with higher quality from cardiac action potentials, and thus be a valuable tool for checking drug side-effect early in the drug discovery pipeline. The Dynamite8 has been developed in collaboration with the UMC Utrecht.
Human iPSC-derived cardiomyocytes (hiPSC-CM's) have become an indispensable tool for safety pharmacologists in recent years for a variety of different assays. We developed a new predictive patch clamp assay in line with the aims of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative by fully integrating the dynamic clamp functionality in the 8-channel Patchliner system for the analysis of cardiac action potentials of hiPSC CM's.
Crucial endpoints for the development of this unit have been Giga-Ohm seals and stable recordings with acceptable success rates on commercially available hiPSC-CM's. Simulating the IK1 ion channel and thus allowing to record from more adult ventricular-like shaped Action Potentials in a higher throughput format was one of our main goals.
"A Dynamic Clamp unit for our automated patch clamp platform, Patchliner, has been desired from our existing customers and contacts for a long time. The Dynamite8 unit will enable them to obtain reliable IC50 curves from cardiac action potentials and to focus on evaluating drugs and check for cardiac side effects before ex vivo or in vivo studies." says Dr. Niels Fertig, CEO and founder of Nanion Technologies.
Dr. Teun de Boer, UMC Utrecht, adds: "The essence of dynamic clamp is that a hybrid model is created by connecting a real cell with a computer simulation of (parts of) a cell. For this, a computer simulation running in real-time - simultaneously with the experiment on the real cell - is necessary. With Nanion's Dynamite8 unit, we have developed a remote-controlled dynamic clamp system integrated in the automated patch clamp device, the Patchliner, in order to increase throughput and develop new predictive assays using hiPSC-CMs that are in line with the aims of the CiPA initiative. "
About Nanion Technologies:
Nanion Technologies is a leading provider of instrumentation for ion channel drug discovery and screening. Founded in 2002, Nanion has grown over the last 17 years to a company with over 100 employees worldwide. With headquarters in Munich, Germany, Nanion has subsidiaries in the USA, Japan, China and Denmark, as well as distribution partners in seven other countries.
For more information, please visit www.nanion.de.
Dr. Niels Fertig, CEO, Nanion Technologies GmbH, Munich, Germany
Phone: +49 89 2190 95-072
About UMC Utrecht:
UMC Utrecht is a leading international university medical center generating, testing, sharing, and applying knowledge on health, illness, and health care for the benefit of patients and society.
An important aspect of work in Dr. de Boer's group from the Department of Medical Physiology (Division of Heart & Lungs) is the development of real-time simulations of ion channels, the so-called dynamic clamp technique. The most important application is to simulate cardiac IK1 channels in hiPSC-CMs. Current focus is to enhance the throughput of this approach, which resulted in the establishment of a fully automated dynamic clamping system, which is now introduced as the Nanion Dynamite8.
For more information, please visit http://www.umcutrecht.nl/medphys
Dr. Teun de Boer, Department of Medical Physiology, University Medical Center Utrecht, The Netherlands
Phone: +31 88758900
View original content to download multimedia:http://www.prnewswire.com/news-releases/launch-of-the-dynamic-clamp-unit-for-the-patchliner--the-dynamite8-300929600.html
SOURCE Nanion Technologies GmbH
Upcoming Life Sciences Events
- March 2020
- : Evolution Summit
- Tokyo: BIO Asia International Conference
- Paris: Europe CEO
Latest company news
European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer